Goldman Sachs’s Carlsmed CARL Stock Holding History

Goldman Sachs’s Portfolio CARL Stock Details CARL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Buy	22,638 +9,038	+66%	+$109K	﹤0.01%	6072
2025 Q4	$168K	Buy	+13,600	New	+$181K	﹤0.01%	6085

Other funds holding CARL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM Capital Shawnee, Kansas $622M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's CARL Position: Q1 2026 in Review

Goldman Sachs increased its Carlsmed (CARL) stake by 66% in Q1 2026, buying an estimated $109K and bringing the position to 22,638 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #6072.

Goldman Sachs first reported a position in CARL in Q4 2025 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold CARL as of Q1 2026.

Goldman Sachs held 22,638 shares of Carlsmed worth $205K as of Q1 2026.
Goldman Sachs bought 9,038 Carlsmed shares in Q1 2026, an estimated $109K.
Carlsmed made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6072 holding.
Goldman Sachs first reported a position in Carlsmed in Q4 2025 and has held it in 2 quarters since.
66 funds tracked by Wall St. Rank held Carlsmed as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.